approval
saveDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approval
community read0 votes
Sponsor: BAXTER HLTHCARE CORP. Form: INJECTABLE, LIPOSOMAL. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalMar 10, 2026 · 208d ago
- approvalDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalAug 12, 2019 · 2610d ago
- approvalDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalMar 29, 2016 · 3841d ago
- approvalDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalDec 28, 2015 · 3933d ago
- approvalDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalOct 9, 2015 · 4013d ago
- approvalDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalApr 16, 2015 · 4189d ago
- approvalDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalJan 22, 2015 · 4273d ago
- approvalDOXIL (LIPOSOMAL) (DOXORUBICIN HYDROCHLORIDE) — FDA approvalApr 14, 2014 · 4556d ago
same company · ±60 days · 3
- approvalMAGNESIUM SULFATE: MAGNESIUM SULFATE — FDA approvalMay 10, 2022
- approvalNOREPINEPHRINE BITARTRATE: NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approvalJun 2, 2022
- approvalNOREPINEPHRINE BITARTRATE: NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (NOREPINEPHRINE BITARTRATE) — FDA approvalJun 2, 2022
comments(0)
5-min edit window · permanent after that